The study by a team of scientists at the
The research, published in the journal Science Immunology, suggests that vaccines for young children are likely important, safe tools to curtail the pandemic.
"The level of potent antibodies we observed were comparable to what has been seen in adult macaques, even though the doses were 30 micrograms instead of the 100 microgram adult doses," said Kristina De Paris,
"With the Moderna vaccine, we observed specific strong T cell responses, as well, which we know are important to limiting disease severity," De Paris added.
To evaluate SARS-CoV-2 infant vaccination, the researchers immunised two groups of 8 infant rhesus macaques at 2.2 months of age and 4 weeks later.
Each animal received one of two vaccine types: a preclinical version of the Moderna mRNA vaccine or a protein-based vaccine developed by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, with an adjuvant from 3M that stimulates cells through toll-like receptor 7 and 8.
Both vaccines elicited high magnitude of IgG neutralising antibodies against SARS-CoV-2 and Spike protein-specific T cell responses -IL-17, IFN-g, and TNF. These are called T helper 1 immune responses.
Importantly, the vaccines did not elicit T helper type 2 responses, which can be detrimental to vaccine efficacy and safety in infants. Such responses can counter the immune response against the virus. And so, T helper 2 responses have hindered the development of vaccines in young children, most notably for the common Respiratory Syncytial Virus (RSV).
SEE ALSO
Gautam Adani loses over $7 billion in net worth after questions over the meteoric rise in group stocks
Adani group, PNB, Coal India, TCS and other stocks to watch out for on June 14
Weekly crypto roundup: WazirX under scrutiny, El Salvador makes Bitcoin legal tender and more